"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Descriptor ID |
D011960
|
MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 0 | 1 |
1995 | 4 | 3 | 7 |
1996 | 6 | 1 | 7 |
1997 | 4 | 2 | 6 |
1998 | 2 | 1 | 3 |
1999 | 2 | 1 | 3 |
2000 | 4 | 0 | 4 |
2001 | 3 | 3 | 6 |
2002 | 2 | 4 | 6 |
2003 | 8 | 2 | 10 |
2004 | 6 | 1 | 7 |
2005 | 3 | 4 | 7 |
2006 | 2 | 3 | 5 |
2007 | 3 | 2 | 5 |
2008 | 4 | 4 | 8 |
2009 | 4 | 4 | 8 |
2010 | 4 | 4 | 8 |
2011 | 3 | 6 | 9 |
2012 | 2 | 7 | 9 |
2013 | 1 | 9 | 10 |
2014 | 3 | 6 | 9 |
2015 | 2 | 3 | 5 |
2016 | 10 | 10 | 20 |
2017 | 0 | 10 | 10 |
2018 | 3 | 10 | 13 |
2019 | 5 | 5 | 10 |
2020 | 3 | 4 | 7 |
2021 | 3 | 5 | 8 |
2022 | 0 | 4 | 4 |
2023 | 0 | 1 | 1 |
2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status. Breast Cancer Res. 2024 Mar 21; 26(1):51.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024 Mar; 25(3):269-270.
-
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer. Cancer Commun (Lond). 2023 05; 43(5):615-619.
-
Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. J Am Coll Surg. 2022 11 01; 235(5):788-798.
-
Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Hum Mol Genet. 2022 09 10; 31(18):3133-3143.
-
Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line. Biophys J. 2022 10 04; 121(19):3651-3662.
-
In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
-
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021 Aug; 189(1):15-23.